Dose effect of psilocybin on primary and secondary depression a preliminary systematic review and meta-analysis.
Previous studies have shown that psilocybin has antidepressant effects. In the current study, we aim to explore the dose effects of psilocybin on primary (major depression patients) and secondary depression (depressed cancer patients). Published studies concerning psilocybin for depression were retrieved. In accordance with PRISMA guidelines, 6 databases (PubMed, Embase, Web of Science, Cochrane Library, Clinicaltrials.gov 2.3 and WanFang database) were searched for research studies published or still in progress from inception to 30 November, 2020, with language restricted to English and Chinese. Hedges g of Beck Depression Inventory (BDI) score changes was calculated as the primary outcome. 7 articles were finally included, with a total of 136 participants. In terms of efficacy, Hedges g was 1.289 (95%CI1.020, 1.558, heterogeneity I Only a small number of studies can be identified of variable quality, thus our conclusions remain preliminary. Our preliminary results have shown that psilocybin exerts a rapid effect in reducing depressive symptom on primary and secondary depression. The optimal dose of psilocybin may be 30-35mg70kg or higher future clinical trials are warranted for further evaluation on its effect.